Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends Baraclude

The National Institute for Health and Clinical Excellence has recommended Bristol-Myers Squibb's drug, Baraclude, for the treatment of chronic hepatitis B
Bristol-Myers Squibb (BMS) has revealed that the National Institute for Health and Clinical Excellence (NICE) has recommended its drug, Baraclude, for the treatment of chronic hepatitis B.

The medicine is an anti-viral medication which the company claims has proven to be more effective at suppressing the virus than the most widely and currently used generic, lamivudine. GlaxoSmithKline (GSK) manufactures Zeffix, Epivir and Epivir-HBV, which are all branded versions of the generic. BMS also says that its chronic hepatitis B treatment is less prone to drug-resistance.

"BMS welcomes the news that NICE has issued a positive final appraisal determination (FAD) recommending Baraclude as a treatment option for all chronic hepatitis B patients, in line with its licence," said Richard Marsh, director of external affairs and market access at the company.

"Baraclude is a clinically effective and cost effective treatment for all eligible patients."

The drug is currently indicated for use in the US for chronic hepatitis B and BMS hopes that a final decision about guidance will be made in August 2008. Marsh said that primary care trusts (PCTs) should make funding available for Baraclude, so GPS can prescribe it for their patients.

25th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics